Serum syndecan-1 level was also higher in LN patients with active disease compared to SLE patients with extrarenal manifestations (53, 56) and this may be attributed, at least in part, to a loss of syndecan-1 from the glomerular endothelial glycocalyx and downstream glomerular injury. This evidence concerns the gene SDC1 and lobular neoplasia.